SCHEMBL4069249

SCHEMBL4069249

C[Si](C)(C)CCOCn1cnc2c(I)cccc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.35
LMNA P02545 4/20 0.35
DGAT1 O75907 1/20 0.35
NPC1 O15118 1/20 0.34
BRD4 O60885 1/20 0.34
CREBBP Q92793 1/20 0.34
EGFR P00533 1/20 0.32
IGF1R P08069 1/20 0.32
SRC P12931 1/20 0.32
FLT4 P35916 1/20 0.32
KDR P35968 1/20 0.32
FLT3 P36888 1/20 0.32
EPHB4 P54760 1/20 0.32
TEK Q02763 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
PDE10A Q9Y233 2/20 0.31
PNP P00491 1/20 0.31
CYP17A1 P05093 1/20 0.31
HPRT1 P00492 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5951884 0.85 DGAT1 (0.38) SMN1; SMN2LMNADGAT1NPC1BRD4
SCHEMBL23122502 0.84 ADA (0.36) SMN1; SMN2LMNADGAT1NPC1BRD4
SCHEMBL15825447 0.84 DGAT1 (0.40) SMN1; SMN2LMNADGAT1NPC1BRD4
SCHEMBL21458046 0.84 DGAT1 (0.37) SMN1; SMN2LMNADGAT1NPC1BRD4
SCHEMBL29117073 0.83 BRD4 (0.39) SMN1; SMN2LMNADGAT1NPC1BRD4
SCHEMBL22717563 0.82 NPC1 (0.37) SMN1; SMN2LMNADGAT1NPC1BRD4
SCHEMBL2128110 0.82 DGAT1 (0.34) SMN1; SMN2LMNADGAT1NPC1BRD4
SCHEMBL23123000 0.82 NPC1 (0.35) SMN1; SMN2LMNADGAT1NPC1BRD4
SCHEMBL2357255 0.80 SMN1; SMN2 (0.56) SMN1; SMN2LMNANPC1L3MBTL1TDP1
SCHEMBL30013328 0.80 SMN1; SMN2 (0.56) SMN1; SMN2LMNANPC1L3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220289753-A1 SHP2 INHIBITORS IRBM S.P.A. (IT) 2022-09-15 US disclosed
US-7592456-B2 Arylsulfonylnaphthalene derivatives as 5HT2A antagonists MERCK SHARP & DOHME LIMITED (GB) 2009-09-22 US disclosed
EP-1824817-B1 ARYLSULFONYLNAPHTHALENE DERIVATIVES AS 5HT2A ANTAGONISTS MERCK SHARP & DOHME (GB) 2009-02-04 EP disclosed
US-20070281952-A1 Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists MERCK SHARPE & DOHME LIMITED (GB) 2007-12-06 US disclosed
EP-1824817-A1 ARYLSULFONYLNAPHTHALENE DERIVATIVES AS 5HT2A ANTAGONISTS MERCK SHARP & DOHME LTD. (GB) 2007-08-29 EP disclosed
WO-2006059149-A1 ARYLSULFONYLNAPHTHALENE DERIVATIVES AS 5HT2A ANTAGONISTS MERCK SHARP & DOHME LIMITED (GB) 2006-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220289753-A1 SHP2 INHIBITORS PTPN1, PTPN2, PTPN7 SMN1; SMN2 4332/4885LMNA 4863/4885DGAT1 1279/4885
US-20070281952-A1 Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists HTR2A, HTR2C, HTR1A SMN1; SMN2 200/4885LMNA 1186/4885DGAT1 4221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.